Puma Biotechnology | PBYI - Bruttoergebnis Vom Umsatz





Bruttoergebnis Vom Umsatz Veränderung Datum
Agios Pharmaceuticals USD 52.86M 11.11M 2026-09
Alnylam Pharmaceuticals USD 930.2M 62.49M 2026-09
Amgen USD 8.46B 1.22B 2026-09
Biogen USD 2.25B 127.8M 2026-09
BioMarin Pharmaceutical USD 719.77M 6.35M 2026-09
Daiichi Sankyo JPY 470.99B 20.54B 2026-09
Exelixis USD 632.46M 24.43M 2026-09
Gilead Sciences USD 6.73B 74M 2026-09
Glaxosmithkline GBP 6.5B 743M 2026-09
Incyte USD 1.45B 120.58M 2026-09
MacroGenics USD 32.83M 21.59M 2026-06
Moderna USD 995M 945M 2026-09
Novartis USD 11.42B 180M 2026-09
Pfizer USD 3.24B 3.49B 2026-09
PTC Therapeutics USD 321.55M 19.05M 2026-09
Puma Biotechnology USD 20.32M 24.85M 2024-09
Regeneron Pharmaceuticals USD 3.71B 778.2M 2026-06
Roche Holding CHF 22.69B 600M 2026-06
Sangamo BioSciences -2.39M 1.09M 2024-06
Sarepta Therapeutics USD 192.12M 59.03M 2026-09
Takeda JPY 795B 18.22B 2026-09
TG Therapeutics USD 199.14M 27.73M 2026-06
Ultragenyx Pharmaceutical USD 141M 39M 2026-09
Vanda Pharmaceuticals USD 50.6M 5.5M 2024-12
Vertex Pharmaceuticals USD 2.94B 99.9M 2026-09